論文

査読有り
2018年1月1日

Clinical outcome of patients with obscure gastrointestinal bleeding during antithrombotic drug therapy

Therapeutic Advances in Gastroenterology
  • Yoshiyasu Kono
  • ,
  • Seiji Kawano
  • ,
  • Yuki Okamoto
  • ,
  • Yuka Obayashi
  • ,
  • Yuki Baba
  • ,
  • Hiroyuki Sakae
  • ,
  • Makoto Abe
  • ,
  • Tatsuhiro Gotoda
  • ,
  • Toshihiro Inokuchi
  • ,
  • Hiromitsu Kanzaki
  • ,
  • Masaya Iwamuro
  • ,
  • Yoshiro Kawahara
  • ,
  • Hiroyuki Okada

11
開始ページ
1756283X17746930
終了ページ
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1177/1756283X17746930
出版者・発行元
SAGE Publications Ltd

Background: The clinical outcome of patients with obscure gastrointestinal bleeding (OGIB) during antithrombotic drug therapy has not been fully investigated. Methods: Patients who underwent video capsule endoscopy (VCE) for the investigation of OGIB at Okayama University Hospital from January 2009 to March 2016 were enrolled. We evaluated the VCE findings, the patterns of OGIB, and the rate of rebleeding within 1 year in antithrombotic drug users and antithrombotic drug nonusers. Results: A total of 181 patients were enrolled. Among the antithrombotic drug users, the rate of VCE positivity in the patients with overt OGIB was significantly higher in comparison with patients with occult OGIB (45% versus 16%, p = 0.014), whereas there was no significant difference among the antithrombotic drug nonusers (27% versus 26%, p = 1.0). Among the antithrombotic drug users, the rate of rebleeding among the VCE-positive patients was significantly higher in comparison with the VCE-negative patients (50% versus 5.9%, p = 0.011). Moreover, among antithrombotic drug users who did not receive therapeutic intervention, the rate of rebleeding among the VCE-positive patients was significantly higher in comparison with the VCE-negative patients (75% versus 6.3%, p = 0.001). However, among the antithrombotic drug nonusers who did not receive therapeutic intervention, the rebleeding rate of the VCE-positive patients was not significantly different from that of the VCE-negative patients (20% versus 9.4%, p = 0.43). Conclusion: Therapeutic intervention should be considered for patients with overt OGIB who are VCE positive and who use antithrombotic drugs due to the high risk of rebleeding.

リンク情報
DOI
https://doi.org/10.1177/1756283X17746930
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29399040
ID情報
  • DOI : 10.1177/1756283X17746930
  • ISSN : 1756-2848
  • ISSN : 1756-283X
  • PubMed ID : 29399040
  • SCOPUS ID : 85041391379

エクスポート
BibTeX RIS